- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.09. | Inflammation biotech Electra Therapeutics charges up with $350M from upsized IPO | ||
| 17.09. | Goa Therapeutics launches with 'immeasurably huge' vision of creating Narcan for alcohol | ||
| 17.09. | After one failed acquisition attempt, Lisata finds lifeline in Marea merger | ||
| 17.09. | North Immunology goes public via reverse merger as eczema drug heads toward clinic | ||
| 17.09. | Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive | ||
| 17.09. | SK pens $315M pact with fellow South Korean company for Parkinson's prospect | ||
| 17.09. | Longeveron's phase 2b stem cell flop spurs cost cutting, exploration of 'all options' | ||
| 16.09. | Novartis ends ALS program after phase 2 flop, adding to R&D woes | ||
| 16.09. | Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier | ||
| 15.09. | FDA launches pilot program to speed up sluggish phase 1 trials | ||
| 15.09. | Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope | ||
| 15.09. | Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech | ||
| 15.09. | Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail | ||
| 15.09. | GSK doubles down on Chimagen with $750M multiple myeloma wager | ||
| 15.09. | Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis | ||
| 15.09. | J&J's Contineum-partnered depression drug flunks another phase 2 test | ||
| 14.09. | Lilly cans early experimental obesity drug after 'high bar' not met | ||
| 14.09. | Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi | ||
| 14.09. | Electra Therapeutics aims for $342M IPO to power inflammatory drug's push through phase 3 | ||
| 14.09. | Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon | ||
| 14.09. | Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival | ||
| 11.09. | FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer | ||
| 11.09. | The future of RAS inhibitors | ||
| 10.09. | Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal | ||
| 10.09. | Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.